Alzex Neuropharma Inc.
TRRI
$0.10
-$0.02-16.67%
| 06/30/2011 | 03/31/2011 | ||||
|---|---|---|---|---|---|
| Revenue | -1.89% | 6.02% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -1.55% | 2.43% | |||
| Cost of Revenue | -13.07% | 17.95% | |||
| Gross Profit | 427.98% | -82.66% | |||
| SG&A Expenses | 373.10% | 484.27% | |||
| Depreciation & Amortization | 4.07% | 245.16% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 1.05% | 39.19% | |||
| Operating Income | -66.49% | -117.34% | |||
| Income Before Tax | -45.48% | -118.52% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -45.48% | -118.52% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -45.48% | -118.52% | |||
| EBIT | -66.49% | -117.34% | |||
| EBITDA | -234.00% | -- | |||
| EPS Basic | -- | -- | |||
| Normalized Basic EPS | -- | -- | |||
| EPS Diluted | -- | -- | |||
| Normalized Diluted EPS | -- | -- | |||
| Average Basic Shares Outstanding | -- | -- | |||
| Average Diluted Shares Outstanding | -- | -- | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
